Enterprise Europe Network
HomeParticipantsMarketplace

ADmit Therapeutics SL

Medical Device Manufacturer

admit-therapeutics.com/en/Barcelona, Spain
3 profile visits

About

ADmit Therapeutics has developed the MAP-AD Test, the first prognostic blood test for Alzheimer's disease (AD) dementia. It is based on novel biomarkers discovered by our team and the IVDR has been developed in Barcelona. Using patented mitochondrial DNA biomarkers and AI, it predicts progression to AD in patients with first memory complaints, even before amyloid positivity. This facilitates early personalized interventions, optimizes clinical trial enrollment, and empowers patients and clinicians with crucial foresight. Our solution improves quality of life and offers significant economic savings.

GENOME RESEARCH

Bioinformatics

LIFE SCIENCE

Diagnostics

E-HEALTH

Health information management

BIOLOGY / BIOTECHNOLOGY

In vitro Testing, Trials

THERAPEUTIC AREA

Neurology

MEDICINE

Neurology, Brain Research

Representatives

CEO

ADmit Therapeutics SL